NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-31
Reading JNJ? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — EPS reaches at least $11.55 in 2026: EPS $10.94-$11.01 vs $11.55.
View ThesisRevenue is growing steadily — about 8% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 17%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look high — the market is pricing in about 35% growth a year, above the roughly 8% analysts expect, leaving little room for error.
View ValuationRelatively steady — typically moves about 1% a day.
View RiskRecent financial performance is strong. Its last earnings result was a beat. Peer multiples imply a price about 44% below where it trades (it looks expensive on this basis). Risk is low. This read is provisional.
Trailing returns as of 2026-07-31. JNJ is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 24 analysts currently covering JNJ (as of Jul 2026).
Based on 13 Wall Street analysts offering 12-month price targets for JNJ in the last 4 months.
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Threatens: Increase 2026 EPS guidance to $11.68
Biotech progress may hinder future EPS growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $256.35
The last 12 months of price, then the range of analyst 12-month targets from today’s $256.35.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Complete strategic acquisitions and partnerships to expand oncology pipeline
FDA Priority Review supports oncology pipeline expansion.
Settlement may impact financial resources and reputation.
Advances: Complete strategic acquisitions and partnerships to expand oncology pipeline
Partnership expands oncology pipeline, aligning with growth objectives.
Advances: Sustain innovation and pipeline progress in key therapeutic areas
Acquisition directly enhances oncology innovation pipeline.
Advances: Sustain innovation and pipeline progress in key therapeutic areas
Positive trial results support innovation in key therapeutic areas.
Proposed resolution may affect future litigation costs.
FDA approval enhances product portfolio and growth potential.
